Taking hydroxychloroquine to heart

hydroxychloroquine (HCQ) was considered (and subsequently refuted) as a potential therapy against the SARS-CoV-2 virus. Reports of cardiotoxicity triggered controversy about appropriate cardiac monitoring in patients who were The antimalarial HCQ is a workhorse in medical including lupus erythematosus, dermatomyositis, and rheumatoid arthritis. Cardiotoxic effects associated with prolonged administration and high dosages of HCQ include bradycardia, tachycardia, block, and cardiomyopathy. Risk factors associated with cardiotoxicity include age [60 years, female nephritis, underlying cardiac disease, the presence of systemic inflammation, and COX inhibition.1,2 Before COVID-19, cardiac monitoring by electrocardiogram